Influence of genetic polymorphisms on the plasma concentrations of oral tyramine applique - pharmacogenetics biogenic amines
Not Applicable
Recruiting
- Conditions
- Healthy participants
- Registration Number
- DRKS00008915
- Lead Sponsor
- Institut für Klinische PharmakologieUniversitätsmedizin Göttingen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Subjects between 18 and 50 years of age. Body weight between 50 and 100 kg, while body mass index 18 to 30.
Exclusion Criteria
Any known chronic disease significantly increasing cardiovascular risk profile. This is but not limited to: Diabetes mellitus, arterial hypertension, heart failure, status post myocardial infarction, Post-bypass OP or percutaneous transluminal angioplasty, Post-stroke, renovascular disease. Known intolerance to tyramine. Need for any regular medication other than oral contraceptives.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Area under the plasma concentration-time curve of tyramine for the first 6 hours after oral administration of 400 mg of tyramine depending on congenital genetic variants with significance for transport proteins, metabolizing enzymes and components relevant to the effects of biogenic amines pathways.
- Secondary Outcome Measures
Name Time Method Plasma concentrations of tyramine before taking 400 mg tyramine, plasma concentrations and area under the plasma concentration-time curves of other endogenous and exogenous biogenic amines insofar as they are detectable (e.g. Adrenalin, Tryptamin, Noradrenalin, Putrescin, Isoamylamin, Dopamin, Cadaverin, Agmatin, Serotonin, Phenylethylamin, Isopropanolamin, Histamin, Spermidin, Cholin, Gamma-Aminobuttersäure, Octopamin, 5-Methoxyindol Ethylamin, Synephrin, 5-Methoxytryptamin, Colamin, Cysteamin, Beta-Alanin), in the urine excreted amounts of primary and secondary amines measured with and without enzymatic cleavage - each depending on congenital genetic variants with significance for transport proteins, metabolizing enzymes and components relevant to the effects of biogenic amines pathways.